Galectin Therapeutics Inc. (GALT)

[sokol]

Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis

The study will be presented at The Liver Meeting® in Washington D.C. on October 19-23, 2017 and is co-authored by investigators involved in the NASH-CX trial. Topline results from the trial will be reported in December, 2017.

http://globenewswire.com/news-release/2017/10/20/1150936/0/en/Galectin-Therapeutics-to-Present-Clinical-Data-at-The-Liver-Meeting-2017-Demonstrating-the-Ability-of-Non-Invasive-Test-to-Identify-Clinically-Significant-Portal-Hypertension-in-Pa.html